Advertisement

Neurotherapeutics

, Volume 16, Issue 3, pp 761–783 | Cite as

PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson’s Disease

  • Wen Yuan Luo
  • Su Qian Xing
  • Ping Zhu
  • Chen Guang Zhang
  • Hui Min Yang
  • Nicholas Van Halm-Lutterodt
  • Li GuEmail author
  • Hong ZhangEmail author
Original Article
  • 257 Downloads

Abstract

Targeting mGluR5 has been an attractive strategy to modulate glutamate excitotoxicity for neuroprotection. Although human clinical trials using mGluR5 negative allosteric modulators (NAMs) have included some disappointments, recent investigations have added several more attractive small molecules to this field, providing a promise that the identification of more additional strategies to modulate mGluR5 activity might be potentially beneficial for the advancement of PD treatment. Here, we determined the role of the interacting partner CAL (cystic fibrosis transmembrane conductance regulator–associated ligand) in mGluR5-mediated protection in vitro and in vivo. In astroglial C6 cells, CAL deficiency blocked (S)-3, 5-dihydroxyphenylglycine (DHPG)-elicited p-AKT and p-ERK1/2, subsequently prevented group I mGluRs-mediated anti-apoptotic protection, which was blocked by receptor antagonist 1-aminoindan-1, 5-dicarboxylic acid (AIDA), and PI3K or MEK inhibitor LY294002 or U0126. In rotenone-treated MN9D cells, both CAL and mGluR5 expressions were decreased in a time- and dose-dependent manner, and the correlation between these 2 proteins was confirmed by lentivirus-delivered CAL overexpression and knockdown. Moreover, CAL coupled with mGluR5 upregulated mGluR5 protein expression by inhibition of ubiquitin-proteasome-dependent degradation to suppress mGluR5-mediated p-JNK and to protect against cell apoptosis. Additionally, CAL also inhibited rotenone-induced glutamate release to modulate mGluR5 activity. Furthermore, in the rotenone-induced rat model of PD, AAV-delivered CAL overexpression attenuated behavioral deficits and dopaminergic neuronal death, while CAL deficiency aggravated rotenone toxicity. On the other hand, the protective effect of the mGluR5 antagonist MPEP was weakened by knocking down CAL. In vivo experiments also confirmed that CAL inhibited ubiquitination-proteasome-dependent degradation to modulate mGluR5 expression and JNK phosphorylation. Our findings show that CAL protects against cell apoptosis via modulating mGluR5 activity, and may be a new molecular target for an effective therapeutic strategy for PD.

Key Words

mGluR5 CAL cell apoptosis ubiquitination Parkinson’s disease 

Notes

Acknowledgements

This study was supported by the National Natural Science Foundation of the People’s Republic of China (81171886; 81372587), Beijing Municipal Natural Science Foundation (No. 7132018), Beijing City Board of Education Development Project (KZ201310025021), and the Project of Construction of Innovative Teams and Teacher Career Development for Universities and Colleges Under Beijing Municipality (No. IDHT20140514). We thank International Science Editing (http://www.internationalscienceediting.com) for editing this manuscript. The authors thank all members in the group for helpful suggestions and discussion.

Supplementary material

13311_2019_730_MOESM1_ESM.pdf (231 kb)
ESM 1 (PDF 230 kb)
13311_2019_730_MOESM2_ESM.rar (8.9 mb)
ESM 2 (rar 8.86 MB)

References

  1. 1.
    Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003; 39: 889–909.CrossRefGoogle Scholar
  2. 2.
    DeLong MR, and Wichmann T. Basal Ganglia Circuits as Targets for Neuromodulation in Parkinson Disease. JAMA Neurol. 2015; 72: 1354–1360.CrossRefGoogle Scholar
  3. 3.
    Pin JP, and Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995; 34: 1–26.CrossRefGoogle Scholar
  4. 4.
    Hsieh M, Ho S, Yeh K, et al. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. Pharmacol Biochem Behav. 2012; 102: 64–71.CrossRefGoogle Scholar
  5. 5.
    Gasparini F, Di Paolo T, and Gomez-Mancilla B. Metabotropic Glutamate Receptors for Parkinson’s Disease Therapy. Parkinson’s Dis. 2013; 2013: 196028.Google Scholar
  6. 6.
    Litim N, Morissette M, and Di Paolo T. Metabotropic glutamate receptors as therapeutic targets in Parkinson’s disease: An update from the last 5 years of research. Neuropharmacology. 2017; 115: 166–179.CrossRefGoogle Scholar
  7. 7.
    Vernon AC, Zbarsky V, Datla KP, Croucher M J, and Dexter DT. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem. 2007; 103: 1075–1091.CrossRefGoogle Scholar
  8. 8.
    Morin N, Grégoire L, Morissette M, et al. MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates. Neuropharmacology. 2013; 66: 355–364.CrossRefGoogle Scholar
  9. 9.
    Duvey G, Perry B, Le Poul E, et al. A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyridine core. Bioorg Med Chem Lett. 2013; 23: 4523–4527.CrossRefGoogle Scholar
  10. 10.
    Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, and Gomez-Mancilla B. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord. 2014; 20: 947–956.CrossRefGoogle Scholar
  11. 11.
    Emmitte KA. mGlu5 negative allosteric modulators: a patent review (2013 - 2016). Expert Opin Ther Pat. 2017; 27: 691–706.CrossRefGoogle Scholar
  12. 12.
    Niswender CM, and Conn PJ. Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease. Annu Rev Pharmacol. 2010; 50: 295–322.CrossRefGoogle Scholar
  13. 13.
    Tu JC, Xiao B, Naisbitt S, et al. Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins. Neuron. 1999; 23: 583–592.CrossRefGoogle Scholar
  14. 14.
    Kitano J, Kimura K, Yamazaki Y, et al. Tamalin, a PDZ Domain-Containing Protein, Links a Protein Complex Formation of Group 1 Metabotropic Glutamate Receptors and the Guanine Nucleotide Exchange Factor Cytohesins. J Neurosci. 2002; 22: 1280–1289.CrossRefGoogle Scholar
  15. 15.
    Paquet M, Asay MJ, Fam SR, et al. The PDZ Scaffold NHERF-2 Interacts with mGluR5 and Regulates Receptor Activity. J Biol Chem. 2006; 281: 29949–29961.CrossRefGoogle Scholar
  16. 16.
    Neudauer CL, Joberty G, and Macara IG. PIST: a novel PDZ/coiled-coil domain binding partner for the rho-family GTPase TC10. Biochem Biophys Res Commun. 2001; 280: 541–547.CrossRefGoogle Scholar
  17. 17.
    Charest A, Lane K, McMahon K, and Housman DE. Association of a novel PDZ domain-containing peripheral Golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6. J Biol Chem. 2001; 276: 29456–29465.CrossRefGoogle Scholar
  18. 18.
    Cheng J, Moyer B D, Milewski M, Loffing J, Ikeda M, Mickle J E, Cutting G R, Li M, Stanton B A, Guggino W B. A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression. J Biol Chem, 2002, 277: 3520–3529.CrossRefGoogle Scholar
  19. 19.
    Cheng J, Wang H, Guggino W B. Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL. J Biol Chem, 2004, 279: 1892–1898.CrossRefGoogle Scholar
  20. 20.
    He J, Bellini M, Xu J, Castleberry A M, Hall R A. Interaction with cystic fibrosis transmembrane conductance regulator-associated ligand (CAL) inhibits beta1-adrenergic receptor surface expression. J Biol Chem, 2004, 279: 50190–50196.CrossRefGoogle Scholar
  21. 21.
    Wente W, Efanov A M, Treinies I, Zitzer H, Gromada J, Richter D, Kreienkamp H. The PDZ/coiled-coil domain containing protein PIST modulates insulin secretion in MIN6 insulinoma cells by interacting with somatostatin receptor subtype 5. FEBS Letters, 2005, 579: 6305–6310.CrossRefGoogle Scholar
  22. 22.
    Wente W, Stroh T, Beaudet A, Richter D, Kreienkamp H J. Interactions with PDZ domain proteins PIST/GOPC and PDZK1 regulate intracellular sorting of the somatostatin receptor subtype 5. J Biol Chem, 2005, 280: 32419–32425.CrossRefGoogle Scholar
  23. 23.
    Xu Z, Oshima K, Heller S. PIST regulates the intracellular trafficking and plasma membrane expression of cadherin 23. BMC Cell Biol, 2010, 11: 80.CrossRefGoogle Scholar
  24. 24.
    Lu R, Stewart L, Wilson J M. Scaffolding protein GOPC regulates tight junction structure. Cell and Tissue Research, 2015, 360: 321–332.CrossRefGoogle Scholar
  25. 25.
    Ito H, Iwamoto I, Morishita R, Nozawa Y, Asano T, Nagata K. Identification of a PDZ protein, PIST, as a binding partner for Rho effector Rhotekin: biochemical and cell-biological characterization of Rhotekin–PIST interaction. Biochemical J, 2006, 397: 389–398.CrossRefGoogle Scholar
  26. 26.
    Ito H, Iwamoto I, Mizutani K, Morishita R, Deguchi T, Nozawa Y, Asano T, Nagata K. Possible interaction of a Rho effector, Rhotekin, with a PDZ-protein, PIST, at synapses of hippocampal neurons. Neurosci Res, 2006, 56: 165–171.CrossRefGoogle Scholar
  27. 27.
    Chen A, Göβling EK, Witkowski L, et al. Regional and subcellular distribution of the receptor-targeting protein PIST in the rat central nervous system. J Comp Neurol, 2012; 520: 889–913.CrossRefGoogle Scholar
  28. 28.
    Orr H T. Lurcher, nPIST, and autophagy. Neuron, 2002, 35: 813–814.CrossRefGoogle Scholar
  29. 29.
    Yue Z, Horton A, Bravin M, DeJager P L, Selimi F, Heintz N. A novel protein complex linking the delta 2 glutamate receptor and autophagy: implications for neurodegeneration in lurcher mice. Neuron, 2002, 35: 921–933.CrossRefGoogle Scholar
  30. 30.
    Cuadra A E. AMPA Receptor Synaptic Targeting Regulated by Stargazin Interactions with the Golgi-Resident PDZ Protein nPIST. J Neurosci, 2004, 24: 7491–7502.CrossRefGoogle Scholar
  31. 31.
    Zhang J, Cheng S, Xiong Y, et al. A novel association of mGluR1a with the PDZ scaffold protein CAL modulates receptor activity. FEBS Lett. 2008; 582: 4117–4124.CrossRefGoogle Scholar
  32. 32.
    Cheng S, Zhang J, Zhu P, et al. The PDZ domain protein CAL interacts with mGluR5a and modulates receptor expression. J Neurochem. 2010; 112: 588–598.CrossRefGoogle Scholar
  33. 33.
    Brabet I, Mary S, Bockaert J, and Pin JP. Phenylglycine derivatives discriminate between mGluR1- and mGluR5-mediated responses. Neuropharmacology. 1995; 34: 895–903.CrossRefGoogle Scholar
  34. 34.
    Sun L, Gu L, Wang S, et al. N-acetylcysteine protects against apoptosis through modulation of group I metabotropic glutamate receptor activity. PLoS One. 2012; 7: e32503.CrossRefGoogle Scholar
  35. 35.
    Zhang Z, Hu F, Liu Y, et al. Activation of type 5 metabotropic glutamate receptor promotes the proliferation of rat retinal progenitor cell via activation of the PI-3-K and MAPK signaling pathways. Neuroscience. 2016; 322: 138–151.CrossRefGoogle Scholar
  36. 36.
    Ribeiro FM, Vieira LB, Pires RGW, Olmo RP, and Ferguson SSG. Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacol Res. 2017; 115: 179–191.CrossRefGoogle Scholar
  37. 37.
    Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002; 22: 7006–7015.CrossRefGoogle Scholar
  38. 38.
    Bové J, Perier C. Neurotoxin-based models of Parkinson’s disease. Neuroscience, 2012, 211: 51–76.CrossRefGoogle Scholar
  39. 39.
    Moriyoshi K, Iijima K, Fujii H, Ito H, Cho Y, and Nakanishi S. Seven in absentia homolog 1A mediates ubiquitination and degradation of group 1 metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U S A. 2004; 101: 8614–8619.CrossRefGoogle Scholar
  40. 40.
    Peng J, and Andersen JK. The role of c-Jun N-terminal kinase (JNK) in Parkinson's disease. IUBMB Life. 2003; 55: 267–271.CrossRefGoogle Scholar
  41. 41.
    Wang S, Zhang C, Sheng X, Zhang X, Wang B, and Zhang G. Peripheral expression of MAPK pathways in Alzheimer’s and Parkinson’s diseases. J Clin Neurosci. 2014; 21: 810–814.CrossRefGoogle Scholar
  42. 42.
    Ambrosi G, Cerri S, and Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease. J Neural Transm (Vienna). 2014; 121: 849–859.CrossRefGoogle Scholar
  43. 43.
    Rodrigues RJ, Alfaro TM, Rebola N, Oliveira CR, and Cunha RA. Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem. 2005; 92: 433–441.CrossRefGoogle Scholar
  44. 44.
    Ning Xia, Qian Zhang, Shu Ting Wang, et al. Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson’s disease model. Free Radic Biol Med. 2015; 89: 567–580.CrossRefGoogle Scholar
  45. 45.
    Picconi B, and Calabresi P. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson’s disease? Mov Disord. 2014; 29: 715–719.CrossRefGoogle Scholar
  46. 46.
    Vallano A, Fernandez-Duenas V, Garcia-Negredo G, et al. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson’s disease: bridging molecular studies and clinical trials. CNS Neurol Disord Drug Targets. 2013; 12: 1128–1142.Google Scholar
  47. 47.
    Ossowska K, Konieczny J, Wolfarth S, and Pilc A. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology. 2005; 49: 447–455.CrossRefGoogle Scholar
  48. 48.
    Morin N, Grégoire L, Gomez-Mancilla B, Gasparini F, and Di Paolo T. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology. 2010; 58: 981–986.CrossRefGoogle Scholar
  49. 49.
    Grégoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord. 2011; 17: 270–276.CrossRefGoogle Scholar
  50. 50.
    Bezard E, Pioli EY, Li Q, et al. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord. 2014; 29: 1074–1079.CrossRefGoogle Scholar
  51. 51.
    Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials. Mov Disord. 2011; 26: 1243–1250.CrossRefGoogle Scholar
  52. 52.
    Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. 2013; 28: 1838–1846.CrossRefGoogle Scholar
  53. 53.
    Tison F, Keywood C, Wakefield M, et al. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016; 31: 1373–1380.CrossRefGoogle Scholar
  54. 54.
    Coccurello R, Breysse N, and Amalric M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology. 2004; 29: 1451–1461.CrossRefGoogle Scholar
  55. 55.
    Armentero M, Fancellu R, Nappi G, Bramanti P, and Blandini F. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis. 2006; 22: 1–9.CrossRefGoogle Scholar
  56. 56.
    Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, and Buckman JF. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience. 1999; 88: 1–16.CrossRefGoogle Scholar
  57. 57.
    Farrand AQ, Gregory RA, Bäckman CM, Helke KL, and Boger HA. Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson’s disease. Brain Res. 2016; 1651: 88–94.Google Scholar
  58. 58.
    Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65: 1–105.CrossRefGoogle Scholar
  59. 59.
    Ismayilova N, Verkhratsky A, and Dascombe MJ. Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats. Eur J Pharmacol. 2006; 545: 134–141.CrossRefGoogle Scholar
  60. 60.
    Yu T, Wang S, Liu J, and Yin H. Changes in the Gene Expression of GABAA Receptor α1 and α2 Subunits and Metabotropic Glutamate Receptor 5 in the Basal Ganglia of the Rats with Unilateral 6-Hydroxydopamine Lesion and Embryonic Mesencephalic Grafts. Exp Neurol. 2001; 168: 231–241.CrossRefGoogle Scholar
  61. 61.
    Pellegrino D, Cicchetti F, Wang X, et al. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. J Nucl Med. 2007; 48: 1147–1153.CrossRefGoogle Scholar
  62. 62.
    Sanchez-Pernaute R, Wang JQ, Kuruppu D, et al. Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage. 2008; 42: 248–251.CrossRefGoogle Scholar
  63. 63.
    Morin N, Morissette M, Gregoire L, Gomez-Mancilla B, Gasparini F, and Di Paolo T. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology. 2013; 73: 216–231.CrossRefGoogle Scholar
  64. 64.
    Copani A, Casabona G, Bruno V, et al. The metabotropic glutamate receptor mGlu5 controls the onset of developmental apoptosis in cultured cerebellar neurons. Eur J Neurosci. 1998; 10: 2173–2184.CrossRefGoogle Scholar
  65. 65.
    Ulus IH, Wurtman RJ. Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices. J Pharmacol Exp Ther. 1997; 281: 149–154.Google Scholar
  66. 66.
    Phillips JM, Lam HA, Ackerson LC, and Maidment NT. Blockade of mGluR5 glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson’s disease. Eur J Neurosci. 2006; 23: 151–160.CrossRefGoogle Scholar
  67. 67.
    Ambrosi G, Armentero MT, Levandis G, Bramanti P, Nappi G, and Blandini F. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson’s disease. Brain Res Bull. 2010; 82: 29–38.CrossRefGoogle Scholar
  68. 68.
    Liu F, Gong X, Zhang G, Marquis K, Reinhart P, and Andree TH. The inhibition of glycogen synthase kinase 3β by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Aβ peptides. J Neurochem. 2005; 95: 1363–1372.CrossRefGoogle Scholar
  69. 69.
    Xiong N, Long X, Xiong J, et al. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson’s disease models. Critical Reviews in Toxicology, 2012; 42: 613–632.CrossRefGoogle Scholar
  70. 70.
    Rangel-Barajas C, Coronel I, and Florán B. Dopamine Receptors and Neurodegeneration. Aging Dis. 2015; 6: 349–368.CrossRefGoogle Scholar
  71. 71.
    Cabello N, Gandia J, Bertarelli DC, et al. Metabotropic glutamate type 5, dopamine D2 and adenosine A2A receptors form higher-order oligomers in living cells. J Neurochem. 2009; 109: 1497–1507.CrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2019

Authors and Affiliations

  1. 1.Department of Neurobiology, School of Basic Medical Sciences, Beijing Institute for Brain Disorders and Key Laboratory for Neurodegenerative Disorders of the Ministry of EducationCapital Medical UniversityBeijingChina
  2. 2.Department of Biochemistry and Molecular BiologyCapital Medical UniversityBeijingChina
  3. 3.Department of Neurosurgery, Beijing Tiantan HospitalCapital Medical UniversityBeijingChina
  4. 4.Department of Orthopaedics and Neurosurgery, Keck Medical CenterUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations